We, therefore, used single-cell RNA sequencing (scRNA-seq) coupled with label-free proteome profiling to identify membrane proteins associated with HGF/MET signaling amplification in GBM and to provide a novel modulator, MPZL1, for HGF/MET-targeted therapy. Here, HGF is linked to glioblastoma.